192 related articles for article (PubMed ID: 37221352)
1. Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
Molife C; Winfree KB; Bailey H; D'yachkova Y; Forshaw C; Kim S; Taipale KL; Puri T
Adv Ther; 2023 Jul; 40(7):3135-3168. PubMed ID: 37221352
[TBL] [Abstract][Full Text] [Related]
2. Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.
Subramanian J; Leighl NB; Choi YL; Chou TY; Gregg J; Hui R; Marchetti A; Silvey M; Makin R; Gillespie-Akar L; Taylor A; Kahangire DA; Bailey T; Chau M; Navani N
Lung Cancer; 2023 Jan; 175():47-56. PubMed ID: 36455396
[TBL] [Abstract][Full Text] [Related]
3. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
He J; Pericone CD; Vanderpoel J
Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
[TBL] [Abstract][Full Text] [Related]
4. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.
Jiang SX; Walton RN; Hueniken K; Baek J; McCartney A; Labbé C; Smith E; Chan SWS; Chen R; Brown C; Patel D; Liang M; Eng L; Sacher A; Bradbury P; Leighl NB; Shepherd FA; Xu W; Liu G; Hurry M; O'Kane GM
Cancer Med; 2019 Dec; 8(18):7542-7555. PubMed ID: 31650705
[TBL] [Abstract][Full Text] [Related]
5. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
Turnsek N; Devjak R; Edelbaher N; Osrajnik I; Unk M; Vidovic D; Jeric T; Janzic U
Radiol Oncol; 2022 Aug; 56(3):371-379. PubMed ID: 35853681
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey.
Bailey H; Lee A; Eccles L; Yuan Y; Burlison H; Forshaw C; Varol N
BMC Cancer; 2023 Jun; 23(1):603. PubMed ID: 37386452
[TBL] [Abstract][Full Text] [Related]
8. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.
de Castro J; Tagliaferri P; de Lima VCC; Ng S; Thomas M; Arunachalam A; Cao X; Kothari S; Burke T; Myeong H; Grattan A; Lee DH
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28748556
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
11. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
13. EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.
Helland Å; Andersen KK; Myklebust TÅ; Johannesen TB; Aarøe J; Enerly E
Cancer Treat Res Commun; 2022; 33():100636. PubMed ID: 36155129
[TBL] [Abstract][Full Text] [Related]
14. Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).
Janžič U; Turnšek N; Dediu M; Donev IS; Lupu R; Teodorescu G; Ciuleanu TE; Pluzanski A
Curr Oncol; 2022 Aug; 29(8):5833-5845. PubMed ID: 36005198
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
[TBL] [Abstract][Full Text] [Related]
17. Study of patient characteristics, treatment patterns,
Winfree KB; Sheffield KM; Cui ZL; Sugihara T; Feliciano J
Curr Med Res Opin; 2022 Jan; 38(1):91-99. PubMed ID: 34544302
[TBL] [Abstract][Full Text] [Related]
18. EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.
Helland Å; Myklebust TÅ; Conte S; Frederiksen LE; Aarøe J; Enerly E
Cancer Treat Res Commun; 2024; 38():100785. PubMed ID: 38190787
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
20. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
